Shares of Medpace Holdings Inc (NASDAQ:MEDP) have earned an average rating of “Buy” from the six ratings firms that are presently covering the company. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $35.00.

A number of equities research analysts have weighed in on MEDP shares. Jefferies Group restated a “hold” rating and set a $34.00 price target on shares of Medpace Holdings in a research report on Monday, November 7th. Credit Suisse Group AG started coverage on Medpace Holdings in a research report on Tuesday, September 6th. They set an “outperform” rating and a $35.00 price target on the stock. Zacks Investment Research upgraded Medpace Holdings from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a research report on Wednesday, November 9th. Robert W. Baird started coverage on Medpace Holdings in a research report on Tuesday, September 6th. They set a “neutral” rating and a $35.00 price target on the stock. Finally, William Blair restated an “outperform” rating on shares of Medpace Holdings in a research report on Tuesday, September 6th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning bought a new position in Medpace Holdings during the third quarter valued at approximately $130,000. Granite Point Capital Management L.P. bought a new position in Medpace Holdings during the third quarter valued at approximately $202,000. Teachers Advisors LLC bought a new position in Medpace Holdings during the third quarter valued at approximately $257,000. BlackRock Group LTD bought a new position in Medpace Holdings during the third quarter valued at approximately $379,000. Finally, Bank of New York Mellon Corp bought a new position in Medpace Holdings during the third quarter valued at approximately $403,000.

Shares of Medpace Holdings (NASDAQ:MEDP) opened at 35.99 on Tuesday. Medpace Holdings has a 12 month low of $26.51 and a 12 month high of $37.56. The company’s 50 day moving average price is $31.20 and its 200 day moving average price is $30.24. The company has a market cap of $1.47 billion and a price-to-earnings ratio of 248.21.

Medpace Holdings (NASDAQ:MEDP) last released its quarterly earnings results on Thursday, November 3rd. The company reported $0.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.34 by $0.06. The firm had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $91.42 million. The business’s revenue for the quarter was up 16.2% compared to the same quarter last year. On average, equities analysts expect that Medpace Holdings will post $1.54 EPS for the current fiscal year.

Medpace Holdings Company Profile

Medpace Holdings, Inc is a holding company. The Company operates as a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company is focused on conducting clinical trials across therapeutic areas, with focus in cardiology, metabolic disease, oncology, endocrinology, central nervous system (CNS), and Anti-Viral and Anti-Infective (AVAI).

5 Day Chart for NASDAQ:MEDP

Receive News & Stock Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related stocks with our FREE daily email newsletter.